RNAscope HPV Assay for E6/E7 mRNA Detection in Head and Neck Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing HPV-related head and neck cancers and cervical lesions are limited by their inability to distinguish between transient HPV infections and premalignant lesions, and they lack sensitivity and specificity for detecting HPV E6/E7 mRNA, which is crucial for determining HPV status and cancer progression.
Innovation Solution
The development of an RNA in situ hybridization (ISH) method using the RNAscope® assay, which employs specific target probe sets and a universal signal amplification system to detect E6/E7 mRNA of high-risk HPV subtypes in tissue samples, allowing for accurate identification of HPV-related cancers and assessment of cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current cervical cancer screening methods (Pap smears and biopsy) are used, then screening can be performed, but they cannot distinguish benign transient HPV infections from premalignant lesions
Solution Approach 1:
The invention changes the detection parameter from general HPV DNA detection to specific E6/E7 mRNA detection. This parameter change enables differentiation between transient infections (which do not express E6/E7 mRNA) and premalignant lesions (which do express E6/E7 mRNA), thereby resolving the contradiction between screening capability and diagnostic accuracy.
Solution Approach 2:
The invention replaces traditional mechanical/cytological methods (Pap smears) with molecular biology methods (RNA in situ hybridization). This substitution enables detection of E6/E7 mRNA expression at the molecular level, providing the ability to distinguish between transient infections and premalignant lesions that was not possible with conventional screening methods.
2Measurement precision
If RT-PCR is used to quantify E6/E7 mRNA, then HPV status can be determined, but the procedure is cumbersome and requires RNA extraction from FFPE tissue
Solution Approach 1:
The invention extracts only the essential function of RT-PCR (E6/E7 mRNA detection) while eliminating the cumbersome steps of RNA extraction and RT-PCR amplification. The RNA in situ hybridization method directly detects E6/E7 mRNA in FFPE tissue sections without requiring RNA extraction, thereby maintaining measurement precision while simplifying the procedure.
Solution Approach 2:
The invention introduces probe sets as intermediaries that directly hybridize to E6/E7 mRNA in tissue sections. These probes serve as mediators between the target mRNA and detection systems, enabling direct detection without the need for RNA extraction or PCR amplification steps required by conventional RT-PCR methods.
3Measurement precision
If RT-PCR is used for E6/E7 mRNA detection, then HPV status can be determined, but it does not register expression in individual tumor cells
Solution Approach 1:
The invention segments the detection process to operate at the single-cell level within tissue architecture. The RNA in situ hybridization method preserves tissue morphology and enables visualization of E6/E7 mRNA expression in individual tumor cells and their spatial distribution, thereby maintaining HPV status determination while preserving spatial expression information that would be lost in bulk RT-PCR analysis.
Solution Approach 2:
The invention creates visual copies of E6/E7 mRNA location and expression level within the tissue context. The in situ hybridization produces detectable signals that copy the spatial distribution and intensity of mRNA expression in individual cells, preserving anatomical and spatial information that is inherent to the tissue sample but lost in conventional RT-PCR methods.
4Productivity
If current methods are used for HPV detection, then screening can be performed, but they lack sensitivity and specificity for detecting HPV E6/E7 mRNA
Solution Approach 1:
The invention employs a dynamic signal amplification system with multiple hybridization steps (probe sets, amplifiers, and detectable probes) that can be adjusted and optimized. This dynamic approach allows enhancement of signal intensity and specificity for E6/E7 mRNA detection while maintaining screening capacity, resolving the contradiction between productivity and measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a highly sensitive and specific means to detect high-risk HPV subtypes, enabling precise determination of HPV-related head and neck cancers and cervical lesions, and predicting cancer progression, thereby improving diagnostic accuracy and treatment planning.
Implementation Method 1
employing specific target probe sets and a universal signal amplification system to detect E6/E7 mRNA of high-risk HPV subtypes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a method and a kit for determining whether a head and neck cancer is HPV-related. In one embodiment, an RNAscope® HPV assay was designed to detect the presence of E6/E7 mRNA of certain high-risk HPV subtypes related to head and neck cancer. The present invention also provides a method and a kit for determining whether a cervical lesion is a benign lesion or a cervical intraepithethial neoplasm lesion. In one embodiment, an RNAscope® HPV assay was designed to detect the presence of E6/E7 mRNA of certain high-risk HPV subtypes related to cervical cancer. The present invention further provides a method for determining the progression of cervical intraepithethial neoplasm based on the spatial pattern and levels of the E6/E7 mRNA of certain high-risk HPV subtypes. The present invention also provides a method for determining the risk of developing cervical cancer in a human diagnosed with cervical intraepithethial neoplasm based on presence and absence of the certain subgroups of high-risk HPV subtypes.